| NCT07061626 | Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma | NOT_YET_RECRUITING | PHASE1 | 2025-09 | 2027-03 | 2027-03 |
| NCT07098806 | Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases | RECRUITING | PHASE1 | 2025-07-02 | 2031-10-02 | 2026-10-02 |
| NCT05460507 | Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment | RECRUITING | PHASE1 | 2024-12-12 | 2028-03-01 | 2028-03-01 |
| NCT05034497 | Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-12-06 | 2026-06-30 | 2025-12-21 |
| NCT01906385 | Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | RECRUITING | PHASE1, PHASE2 | 2015-06-03 | 2025-12 | 2025-12 |